COVID-19 Update | July 31, 2020
July 31, 2020
The California Biotechnology Foundation is committed to keeping you up to date about COVID-19 testing, treatment and prevention advancements. The following resources track what progress has been made as of July 31, 2020. Notable advancements include:
- Moderna announced that its COVID-19 vaccine is moving into the final phase of testing with a study of 30,000 participants.
- Pfizer’s COVID-19 vaccine is moving into the third phase of testing at 120 clinical sites worldwide.
- Merck has scheduled large-scale studies for its oral coronavirus treatment in collaboration with Ridgeback Biotherapeutics as early as September.
- Merck aims to start ‘large pivotal’ studies on coronavirus treatment in September
CNBC – July 31, 2020
Merck has scheduled “very large pivotal studies” for its oral coronavirus treatment in collaboration with Ridgeback Biotherapeutics as early as September, a company executive announced.
- Pfizer executive targets end of year for COVID-19 vaccine
Associated Press – July 30, 2020
Meg Ruesch, research and development leader at Pfizer Inc.’s Andover, Massachusetts, facility, said that the company hopes to have their coronavirus vaccine ready by the end of the year.
- FDA Nears Decision Authorizing COVID-19 Treatment With Convalescent Plasma
Wall Street Journal – July 29, 2020
The Food and Drug Administration is nearing a decision to authorize emergency use of antibody-rich blood plasma from recovered COVID-19 patients for treating those infected with the coronavirus, people familiar with the matter said.
- Pfizer and BioNTech Begin Global Phase II/III COVID-19 Vaccine Trial
Biospace – July 28, 2020
Pfizer and BioNTech announced their COVID-19 vaccine global Phase II/III safety and efficacy clinical trial will be conducted in 120 clinical sites around the world, including 39 states in the U.S. Argentina, Brazil and Germany.
- Moderna’s COVID-19 Vaccine Candidate Heads To Widespread Testing In U.S.
NPR – July 27, 2020
The COVID-19 vaccine candidate made by the U.S. biotech company Moderna and developed in collaboration with the National Institutes of Health starts its final phase of testing Monday.
- AstraZeneca pledges $174M to ramp up coronavirus vaccine supply deal with Emergent
Fierce Pharma – July 27, 2020
With a $174 million manufacturing pact signed Monday, Maryland-based Emergent BioSolutions will help produce bulk drug substance for AstraZeneca and Oxford’s COVID-19 vaccine starting this year.
- This Bay Area company thought it might not survive. Then it started making coronavirus proteins
San Francisco Chronicle – July 26, 2020
Atum, a 17-year-old Newark firm specializing in making synthetic genes and proteins, is now playing a vital role in supplying cellular pieces to researchers who use them to build coronavirus antibody tests, drugs and vaccine candidates.
- Scientists Are Researching Ways To Transfuse Antibodies In Coronavirus Treatment
NPR – July 24, 2020
Scientists are trying to figure out whether they can prevent COVID-19 in people at high risk of getting it by infusing them with those antibodies.
Rely on California Biotechnology Foundation to monitor breaking news and provide updates on the latest advancements in COVID-19 diagnostics, vaccines and treatments.
Stay informed on the latest news and trends on the economic and health benefits of this industry by visiting the new CABiotech.org
If you have any questions about informational briefings contact California Biotechnology Foundation Executive Director Patty Cooper at (916)764-2434 or email@example.com.